BrainStorm Cell Therapeutics Aktie

NEW YORK , June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial.» Mehr auf prnewswire.com

NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey.» Mehr auf prnewswire.com

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Bob Dagher - Executive Vice President & Chief Medical Officer Netta Blondheim-Shraga - Senior Vice President, Research & Development Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode.» Mehr auf seekingalpha.com